Belzutifan

The combination of belzutifan and cabozantinib showed promising antitumor activity among patients with previously treated metastatic clear cell renal cell carcinoma, according to data published in The Lancet Oncology.

Belzutifan demonstrated clinical efficacy among patients with von Hippel-Lindau disease-associated renal cell carcinoma, according to results of a phase 2 study published in The New England Journal of Medicine.

The FDA approved belzutifan for treatment of cancers associated with von Hippel-Lindau disease.

The FDA granted priority review to belzutifan for treatment of certain patients with renal cell carcinoma.